About 1 in 10 people suffer from recurring herpes labialis1 in France. Patients have an average of 3,4 episodes each year, which significantly affect their personal and social life2.
Vectans Pharma launches a therapeutic innovation in France for treating recurrences of herpes labialis in immunocompetent adults who experience frequent outbreaks of herpes. This is the very first treatment that allows a single-dose administration of 50 mg of acyclovir for each herpes labialis episode, now available in pharmacy.
In order to insure a successful launch, Vectans Pharma notably relies on a dedicated team in charge of promoting the product.
Thus, dermatologists, general practicioners and pharmacists can discover this new therapeutic treatment in herpes labialis.
1) Lara El Hayderi and Arjen F. Nikkels. Infections par les virus herpès simplex 1 et 2, In Dermatologie infectieuse, edited by Mourad Mokni, Nicolas Dupin and Pascal del Giuduce, Elsevier Masson, Paris, 2014, Pages 7-16, ISBN 9782294732843, https://doi.org/10.1016/B978-2-294-73284-3.00002-8.
2) Dreno B, Malkin J-E, Saiag P. Understanding recurrent herpes labialis management and impact on patients’ quality of life: the HERPESCOPE study. Eur J Dermatol 2013; 23(4): 491-9.